Anaptysbio (ANAB) Common Equity (2016 - 2026)

Anaptysbio has reported Common Equity for 11 years, with the latest figure at $12.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 62.53% year-over-year to $12.7 million; the trailing twelve-month figure through Mar 2026 stood at $12.7 million (down 62.53% YoY), and the FY2025 full-year result was $37.2 million, down 47.49% from the prior year.
• Common Equity for Q1 2026 stood at $12.7 million, down from $37.2 million in the prior quarter.
• The five-year high for Common Equity was $330.7 million in Q1 2022, with the low at -$44.7 million in Q2 2025.
• Historically, Common Equity has averaged $114.4 million across 5 years, with a median of $84.4 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity dropped 13.4% — and 2025, when it sank 552.81%.
• Anaptysbio's Common Equity stood at $262.1 million in 2022, then slumped by 66.39% to $88.1 million in 2023, then declined by 19.56% to $70.9 million in 2024, then tumbled by 47.49% to $37.2 million in 2025, then tumbled by 65.74% to $12.7 million in 2026.
• The last three Common Equity figures came in at $12.7 million (Q1 2026), $37.2 million (Q4 2025), and -$29.4 million (Q3 2025), per Business Quant data.